PHAR Pharming Group N.V. Stock Quote

PHAR [NASD]

Healthcare | Biotechnology | Netherlands

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	63.88M	Perf Week	-6.73%
Market Cap	619.66M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	63.04M	Perf Month	-7.58%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.28%	Short Float	0.00%	Perf Quarter	-21.03%
Sales	174.40M	P/S	3.55	EPS this Y	-	Inst Trans	-	Short Ratio	0.54	Perf Half Y	-31.69%
Book/sh	-	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	9.70 - 21.99	Perf YTD	-36.16%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-55.89%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	0.00%	ATR	0.30
Employees	262	Current Ratio	-	Sales Q/Q	5.00%	Oper. Margin	-	RSI (14)	35.97	Volatility	1.52% 1.53%
Optionable	No	Debt/Eq	-	EPS Q/Q	-50.10%	Profit Margin	-	Rel Volume	0.27	Prev Close	9.71
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.58K	Price	9.70
Recom	-	SMA20	-6.01%	SMA50	-10.63%	SMA200	-23.26%	Volume	424	Change	-0.14%

Sep-14-21 01:00AM	Pharming announces results from clinical trials for the treatment of COVID-19 with RUCONEST® PR Newswire
Aug-05-21 01:00AM	Pharming Group reports financial results for the first half of 2021 PR Newswire -6.78%
Jul-20-21 01:00AM	Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa PR Newswire
Jul-01-21 10:35AM	Orchard Therapeutics, Pharming Ink Development Pact For Gene Therapy Benzinga
01:38AM	Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo HSC Gene Therapy for Hereditary Angioedema PR Newswire
01:00AM	Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema GlobeNewswire
Jun-23-21 01:00AM	Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome PR Newswire
Jun-18-21 01:00AM	Pharming appoints Anurag Relan as Chief Medical Officer and Robert Friesen as Chief Scientific Officer PR Newswire
Jun-04-21 01:00AM	Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain PR Newswire
Jun-01-21 01:00AM	Pharming Group to present at Jefferies Virtual Healthcare Conference PR Newswire
May-19-21 04:31PM	Pharming Reports on Annual General Meeting of Shareholders PR Newswire
May-17-21 01:00AM	Pharming celebrates the 10th annual "hae day :-)" PR Newswire
May-13-21 01:00AM	Pharming Group reports financial results for the first quarter of 2021 PR Newswire -8.40%
Apr-22-21 01:00AM	Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction PR Newswire
Apr-07-21 04:00PM	Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission PR Newswire +5.04%
Apr-06-21 05:30PM	Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM PR Newswire
Mar-23-21 02:00AM	Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors PR Newswire
Mar-16-21 08:10AM	Pharming Group to present at 31st Annual Oppenheimer Healthcare Conference PR Newswire
Mar-11-21 01:00AM	Pharming Group to Present at BioCapital Europe 2021 PR Newswire
Mar-04-21 01:00AM	Pharming Group reports financial results for full year 2020 PR Newswire
Mar-02-21 01:00AM	Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada PR Newswire

Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre- eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience